Masimo Corporation (MASI) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals positive sentiment with strong financial metrics, optimistic guidance, and strategic growth initiatives. The company projects significant revenue and EPS growth, improved operating margins, and successful tariff impact mitigation. The Q&A session highlights opportunities in Philips' installed base and confidence in revenue objectives. Despite some uncertainties, the focus on advanced monitoring, wearables, and AI integration indicates a positive outlook. The overall sentiment suggests a positive stock price reaction over the next two weeks.
Key Financial Performance
Revenue Revenue grew 8% year-over-year, driven by strong underlying demand for innovative technology.
Operating Margin Operating margin expanded by 450 basis points year-over-year, attributed to higher revenue, cost efficiencies, and product improvements. Excluding tariffs, the operating margin would have been 28.5%.
Adjusted Earnings Per Share (EPS) Adjusted EPS increased by 38% year-over-year, supported by margin expansion and solid revenue growth.
Healthcare Revenue Healthcare revenue was $371 million, representing 8% growth year-over-year, driven by strong demand trends.
Consumables Growth Consumables grew 1% year-over-year, compared to a 20% growth rate in the third quarter of 2024, due to unusual year-over-year comparisons.
Capital Equipment and Other Revenues Capital equipment and other revenues grew 67% year-over-year, compared to a decline of 33% last year.
Incremental Value of New Contracts The incremental value of new contracts secured in the third quarter reached $124 million, marking a 48% year-over-year increase, driven by strong U.S. commercial team performance.
Unrecognized Contract Revenue Unrecognized contract revenue expected to be realized within the next 12 months was $507 million, a 17% year-over-year increase.
Technology Boards and Monitors Shipped 66,000 technology boards and monitors were shipped, an 8% increase year-over-year, reflecting sustained and accelerating demand.
Gross Margin Gross margin was 62.2%, a decline of 70 basis points year-over-year due to tariff impacts outweighing operational improvements. Tariffs increased cost of sales by $5 million.
Operating Cash Flow Operating cash flow was $57 million, reflecting strong financial performance.
Proceeds from Sound United Divestiture Net proceeds of $328 million were secured from the divestiture of Sound United, with $56 million used to repay debt and $350 million returned to shareholders through stock repurchases.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Innovative Technology: Revenue grew 8% in the quarter driven by strong demand for innovative technology.
AI-enabled sensors and monitors: Developing next-gen monitors and sensors using AI and machine learning, including a hospital solution for opioid-induced respiratory depression detection.
Wearables: Innovating wearable technology, including findings from Dartmouth-Hitchcock Medical Center study showing cost-effectiveness and operational benefits.
Strategic partnership with Philips: Expanded partnership with Philips to enhance collaboration and innovation.
Capnography growth: Secured a significant contract in the Southeast region, driving growth in capnography.
Operating margin expansion: Achieved 450 basis points of operating margin expansion due to higher revenue and cost efficiencies.
Contracting performance: Secured $124 million in new contracts, a 48% year-over-year increase, marking the strongest third quarter contracting performance in company history.
Revenue guidance: Tightened full-year revenue guidance to $1.510 billion to $1.530 billion.
Divestiture of Sound United: Completed sale of Sound United to Harman, generating $328 million in net proceeds.
Capital deployment: Repurchased $350 million of common stock and repaid $56 million of debt, optimizing capital structure.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff-related costs: Tariffs increased the cost of sales by $5 million in the quarter, causing a margin erosion of 140 basis points. This represents a significant financial burden and impacts gross margins negatively.
Shift to distributor model in international markets: The transition to a distributor model in some international markets created a $6 million headwind to full-year revenue guidance, which could affect revenue growth and market penetration.
Regulatory requirements for opioid-related adverse events: In 2026, CMS will require hospitals to report opioid-related adverse events as a new electronic quality measure. This regulatory requirement could pose challenges for hospitals and necessitate adoption of new technologies.
Foreign exchange impacts: Foreign exchange benefits of $4 million were realized, but fluctuations in currency exchange rates could pose risks to financial performance.
Competitive pressures: Competitor studies have been performed on healthy patients, which may not reflect real-world conditions. This could create challenges in demonstrating superior performance in competitive markets.
Operational challenges due to technical difficulties: Technical difficulties during the call, such as echo and disconnections, may reflect broader operational inefficiencies or communication challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has tightened its full-year revenue guidance to a range of $1.510 billion to $1.530 billion, compared to the prior range of $1.505 billion to $1.535 billion. This adjustment accounts for foreign exchange benefits of $4 million and a $6 million headwind from switching to a distributor model in some international markets.
Operating Margin Guidance: The company has raised its operating margin guidance to a range of 27.3% to 27.7%, representing an increase of 25 basis points at the midpoint compared to the prior guidance range of 27% to 27.5%.
Earnings Per Share (EPS) Guidance: The company has increased its EPS guidance to a range of $5.40 to $5.55, up from the prior range of $5.20 to $5.45. This increase is driven by improvements in operating margin, share repurchases, and a reduction in interest expense.
2026 Guidance: The company will return to a typical 52-week fiscal year in 2026 and will provide more details when initiating formal 2026 guidance.
AI and Machine Learning Integration: The company plans to launch next-generation AI-enabled patient monitors and smart sensors in 2026, including technology to detect opioid-induced respiratory depression (OIRD). This aligns with CMS requirements for hospitals to report opioid-related adverse events starting in 2026.
Wearable Technology and Telehealth: The company is piloting wearable technology and telehealth solutions globally to address unmet patient needs and plans to share more details at the upcoming Investor Day on December 3.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The company repurchased $163 million of common stock by the end of the third quarter and an additional $187 million in the fourth quarter, totaling $350 million. This repurchase involved 2.4 million shares over the third and fourth quarters. The repurchase was funded by proceeds from the divestiture of Sound United and was part of a disciplined approach to capital deployment aimed at enhancing long-term shareholder value.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How do we think about the rest of the year and the potential for further outperformance in the short run? What would the drivers be, and how does this set us up for 2026?
A:Micah Young stated that they do not provide guidance for 2026 during the third quarter call. However, he highlighted strength in contracting during Q3, expecting a strong finish in Q4 with increased shipments in consumables. This will drive acceleration in consumable growth and set them up well for the next year. Catherine Szyman added that profitability improvements are partly due to share buybacks and operational improvements, with $0.08 of EPS guidance increase from buybacks and $0.05 from operational improvements.
Q:Where are you in the process of enhancing commercial excellence at Masimo, and what is the expected impact?
A:Catherine Szyman explained that they are focusing on specialty categories to match the success in pulse oximetry. Strategic investments have been made in capnography, hemodynamics, and brain monitoring. Small wins are being observed, and momentum is expected to pick up more significantly next year.
Q:Can you expand on the share gains in Philips and provide more details on the confidence in future share gains?
A:Catherine Szyman mentioned that due to confidentiality, specific positions in Philips' installed base cannot be disclosed. However, Masimo started with almost zero market share in Philips' installed base in 2016 and is still under-indexed compared to its global market share of 50+%. This presents an opportunity for growth in Philips' installed base.
Q:How should we interpret the trend line in unrecognized contract revenue, and does it give confidence in revenue growth objectives?
A:Micah Young explained that one-third of revenues are contracted and come through shipments. Good growth is being observed, driven by incremental contracts feeding into unrecognized contract revenue. While this does not indicate overall revenue growth at the same level, it provides confidence in delivering revenue growth objectives.
Q:What was unusual about the third quarter last year, and will consumables return to a normal growth rate?
A:Micah Young noted that inpatient admission growth was about 4% last year, with higher ordering patterns creating a tough comparison. Consumables grew 20% in Q3 last year, but on a two-year basis, double-digit growth is observed. Catherine Szyman added that increased shipments in Q4 are expected to accelerate growth.
Q:What is the $6 million distributor call-out, and is it included in the guidance?
A:Micah Young confirmed that the $6 million revenue headwind from moving to a distributor model in some international markets is included in the guidance. This shift is expected to drive more sustainable growth and is neutral to earnings and margins.
Q:Was there anything one-time in the consumables sequential move from Q2 to Q3?
A:Micah Young explained that the large international contract drove sizable consumer revenue in Q2, with higher shipments expected in Q4 under the same contract. This supports confidence in accelerated growth in Q4.
Q:Can you provide context on the growth in advanced monitoring in Q3 versus the first half of the year?
A:Catherine Szyman stated that while specific growth rates are not disclosed until year-end, there is an acceleration in advanced monitoring growth consistent with their strategy, targeting double-digit growth in these categories.
Q:Is the wearables strategy based on existing products or new hardware, and what is the timing?
A:Catherine Szyman mentioned that existing products like Radius VSM, W1, and Radius PPG are being piloted or prepared for launch. Radius VSM is in pilot at major institutions, W1 is used for telehealth and piloted outside the U.S., and Radius PPG is in pilot phase with Philips collaboration, expected to launch in 1-2 years.
Q:What is the timing and regulatory status of the AI algorithm for opioid-induced respiratory depression?
A:Catherine Szyman stated that the algorithm has FDA clearance, and they are submitting it for integration into their monitors and Smart set technology. The launch is expected towards the end of next year.
Q:What are the puts and takes impacting Q4 growth guidance?
A:Micah Young explained that Q4 growth will be driven by acceleration in consumables, particularly from a large OUS contract, while capital growth is expected to be lower. Consumables will see outsized growth, partially offset by softness in capital.
Q:Why is Masimo still below its natural share in Philips' installed base, and why could the next 5 years be better?
A:Catherine Szyman explained that gaining share in Philips' installed base takes time due to 5-year contract cycles. While progress has been made, there is still a gap to close, presenting an opportunity for growth.
Q:What is the broader capital allocation framework after using sale proceeds for share repurchases and debt repayment?
A:Micah Young stated that they will focus on share repurchases and tuck-in technologies to augment their portfolio in hospitals, including wearables, sensors, and monitoring capabilities.
Q:How will the expanded partnership with Philips influence the product roadmap and revenue mix?
A:Catherine Szyman stated that the partnership will help drive growth and presence, particularly in advanced monitoring categories. However, the product mix is not expected to change dramatically in the short term.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on Masimo's position in Philips' installed base due to confidentiality. They also did not disclose specific growth rates for advanced monitoring categories or provide detailed timing for the Philips collaboration on Radius PPG. Additionally, they deferred outlining the broader capital allocation framework and product pipeline details to the upcoming Investor Day.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI machine
AI patient
AI sensor
CEO CFO
CMS hospital
Center surveillance
Collaborations ability
Dartmouth Hitchcock
Difficulty Vice
Difficulty expansion
Technical Difficulty
account
accuracy
curve
demand
depression
detection
echo
event
expansion share
finding
health
level care
milestone
outcome
patient skin
reduction rescue
reporting
skin tone
solution
study Dartmouth
transfer
use hospital
wave
wearable
year Technical
MASI Transcript
Masimo Corporation (MASI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Masimo Corporation (MASI) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call reveals positive sentiment with strong financial metrics, optimistic guidance, and strategic growth initiatives. The company projects significant revenue and EPS growth, improved operating margins, and successful tariff impact mitigation. The Q&A session highlights opportunities in Philips' installed base and confidence in revenue objectives. Despite some uncertainties, the focus on advanced monitoring, wearables, and AI integration indicates a positive outlook. The overall sentiment suggests a positive stock price reaction over the next two weeks.
Masimo Corporation (MASI) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Neutral9-4
Masimo Corporation (MASI) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call presented a mixed picture: strong EPS growth and improved margins were overshadowed by unchanged revenue guidance and tariff impacts. Positive feedback on sales restructuring and strong partnerships were tempered by management's vague responses on future initiatives. The Q&A highlighted uncertainties about the timing of new products and sales impacts. The stock price is likely to remain stable due to these mixed signals, with no clear catalyst for significant movement in either direction.
MASI Slides
MASI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
